JP2017503850A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017503850A5 JP2017503850A5 JP2016554306A JP2016554306A JP2017503850A5 JP 2017503850 A5 JP2017503850 A5 JP 2017503850A5 JP 2016554306 A JP2016554306 A JP 2016554306A JP 2016554306 A JP2016554306 A JP 2016554306A JP 2017503850 A5 JP2017503850 A5 JP 2017503850A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- salt
- alkyl
- pharmaceutical composition
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 15
- 150000003839 salts Chemical class 0.000 claims 12
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 125000005037 alkyl phenyl group Chemical group 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- IQXXEPZFOOTTBA-UHFFFAOYSA-N 1-benzylpiperazine Chemical compound C=1C=CC=CC=1CN1CCNCC1 IQXXEPZFOOTTBA-UHFFFAOYSA-N 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 1
- 125000004414 alkyl thio group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- -1 aralkoxy Chemical group 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- 125000004659 aryl alkyl thio group Chemical group 0.000 claims 1
- 125000005135 aryl sulfinyl group Chemical group 0.000 claims 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims 1
- 125000005110 aryl thio group Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000001589 carboacyl group Chemical group 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361904718P | 2013-11-15 | 2013-11-15 | |
| US61/904,718 | 2013-11-15 | ||
| US14/208,657 US9265765B2 (en) | 2013-03-13 | 2014-03-13 | 7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-A]pyrido[4,3-D]pyrimidin-5(3H)-one, salts thereof and methods of using the same in combination therapy |
| US14/208,657 | 2014-03-13 | ||
| US14/341,392 | 2014-07-25 | ||
| USPCT/US2014/048241 | 2014-07-25 | ||
| US14/341,392 US9376437B2 (en) | 2013-03-13 | 2014-07-25 | 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy |
| PCT/US2014/048241 WO2015073072A1 (en) | 2013-11-15 | 2014-07-25 | 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one |
| PCT/US2014/055373 WO2015073109A1 (en) | 2013-11-15 | 2014-09-12 | 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one, salts thereof and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019233099A Division JP2020097577A (ja) | 2013-11-15 | 2019-12-24 | ７−ベンジル−４−（２−メチルベンジル）−２，４，６，７，８，９−ヘキサヒドロイミダゾ［１，２−ａ］ピリド［３，４−ｅ］ピリミジン−５（１ｈ）−オン、その塩及びその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017503850A JP2017503850A (ja) | 2017-02-02 |
| JP2017503850A5 true JP2017503850A5 (enExample) | 2017-10-12 |
| JP6670751B2 JP6670751B2 (ja) | 2020-03-25 |
Family
ID=53057842
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016554306A Active JP6670751B2 (ja) | 2013-11-15 | 2014-09-12 | ７−ベンジル−４−（２−メチルベンジル）−２，４，６，７，８，９−ヘキサヒドロイミダゾ［１，２−ａ］ピリド［３，４−ｅ］ピリミジン−５（１ｈ）−オン、その塩及びその使用方法 |
| JP2019233099A Pending JP2020097577A (ja) | 2013-11-15 | 2019-12-24 | ７−ベンジル−４−（２−メチルベンジル）−２，４，６，７，８，９−ヘキサヒドロイミダゾ［１，２−ａ］ピリド［３，４−ｅ］ピリミジン−５（１ｈ）−オン、その塩及びその使用方法 |
| JP2022076459A Pending JP2022105170A (ja) | 2013-11-15 | 2022-05-06 | ７－ベンジル－４－（２－メチルベンジル）－２，４，６，７，８，９－ヘキサヒドロイミダゾ［１，２－ａ］ピリド［３，４－ｅ］ピリミジン－５（１ｈ）－オン、その塩及びその使用方法 |
| JP2024027134A Active JP7870305B2 (ja) | 2013-11-15 | 2024-02-27 | ７－ベンジル－４－（２－メチルベンジル）－２，４，６，７，８，９－ヘキサヒドロイミダゾ［１，２－ａ］ピリド［３，４－ｅ］ピリミジン－５（１ｈ）－オン、その塩及びその使用方法 |
| JP2026020546A Pending JP2026086693A (ja) | 2013-11-15 | 2026-02-11 | ７－ベンジル－４－（２－メチルベンジル）－２，４，６，７，８，９－ヘキサヒドロイミダゾ［１，２－ａ］ピリド［３，４－ｅ］ピリミジン－５（１ｈ）－オン、その塩及びその使用方法 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019233099A Pending JP2020097577A (ja) | 2013-11-15 | 2019-12-24 | ７−ベンジル−４−（２−メチルベンジル）−２，４，６，７，８，９−ヘキサヒドロイミダゾ［１，２−ａ］ピリド［３，４−ｅ］ピリミジン−５（１ｈ）−オン、その塩及びその使用方法 |
| JP2022076459A Pending JP2022105170A (ja) | 2013-11-15 | 2022-05-06 | ７－ベンジル－４－（２－メチルベンジル）－２，４，６，７，８，９－ヘキサヒドロイミダゾ［１，２－ａ］ピリド［３，４－ｅ］ピリミジン－５（１ｈ）－オン、その塩及びその使用方法 |
| JP2024027134A Active JP7870305B2 (ja) | 2013-11-15 | 2024-02-27 | ７－ベンジル－４－（２－メチルベンジル）－２，４，６，７，８，９－ヘキサヒドロイミダゾ［１，２－ａ］ピリド［３，４－ｅ］ピリミジン－５（１ｈ）－オン、その塩及びその使用方法 |
| JP2026020546A Pending JP2026086693A (ja) | 2013-11-15 | 2026-02-11 | ７－ベンジル－４－（２－メチルベンジル）－２，４，６，７，８，９－ヘキサヒドロイミダゾ［１，２－ａ］ピリド［３，４－ｅ］ピリミジン－５（１ｈ）－オン、その塩及びその使用方法 |
Country Status (25)
| Country | Link |
|---|---|
| EP (4) | EP3546461B1 (enExample) |
| JP (5) | JP6670751B2 (enExample) |
| KR (5) | KR102742700B1 (enExample) |
| CN (2) | CN106163524B (enExample) |
| AU (4) | AU2014349150B2 (enExample) |
| BR (1) | BR112016011072B1 (enExample) |
| CA (2) | CA2930535C (enExample) |
| CY (2) | CY1121628T1 (enExample) |
| DK (2) | DK3546461T3 (enExample) |
| EA (1) | EA033744B1 (enExample) |
| ES (2) | ES2895600T3 (enExample) |
| HR (2) | HRP20190814T1 (enExample) |
| HU (2) | HUE043291T2 (enExample) |
| IL (6) | IL296386B2 (enExample) |
| LT (2) | LT3546461T (enExample) |
| ME (1) | ME03387B (enExample) |
| MX (3) | MX2016006318A (enExample) |
| PL (2) | PL3068401T3 (enExample) |
| PT (2) | PT3546461T (enExample) |
| RS (2) | RS62572B1 (enExample) |
| SG (1) | SG10201809189UA (enExample) |
| SI (2) | SI3546461T1 (enExample) |
| SM (2) | SMT201900291T1 (enExample) |
| TR (1) | TR201906711T4 (enExample) |
| WO (1) | WO2015073109A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT201900291T1 (it) | 2013-11-15 | 2019-07-11 | Oncoceutics Inc | 7-benzil-4-(2-metilbenzil)-2,4,6,7,8,9-esaidriomidazo[1,2-a]pirido[3,4-e]pirimidin-5(1h)-one, suoi sali e metodi d'uso |
| SMT202500087T1 (it) | 2015-01-30 | 2025-03-12 | Oncoceutics Inc | Derivati di 7-benzil-4-(2-metilbenzil)-2,4,6,7,8,9-esaidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(1h)-one, loro sali e loro uso in terapia |
| WO2017132661A2 (en) * | 2016-01-29 | 2017-08-03 | Oncoceutics, Inc. | G protein-coupled receptor (gpcr) modulation by imipridones |
| MY199595A (en) | 2016-03-02 | 2023-11-08 | Eisai R&D Man Co Ltd | Eribulin-based antibody-drug conjugates and methods of use |
| US11091483B2 (en) * | 2016-08-12 | 2021-08-17 | Madera Therapeutics, LLC | Protein kinase regulators |
| US11040027B2 (en) | 2017-01-17 | 2021-06-22 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| US10172862B2 (en) * | 2017-01-30 | 2019-01-08 | Oncoceutics, Inc. | Imipridones for gliomas |
| JP2022500408A (ja) * | 2018-09-12 | 2022-01-04 | デノボ バイオファーマ エルエルシー | エンザスタウリンとｂｔｋの阻害剤との組合せおよびその使用 |
| US12636293B2 (en) | 2019-04-04 | 2026-05-26 | Cmtx Biotech Inc. | Methods of treating charcot-marie-tooth disease |
| KR102536315B1 (ko) | 2020-09-11 | 2023-05-25 | 아주대학교산학협력단 | 네라티닙을 유효성분으로 포함하는 퇴행성 관절염 예방 또는 치료용 조성물 |
| CN117599041B (zh) * | 2024-01-22 | 2024-05-03 | 中国人民解放军军事科学院军事医学研究院 | 去氢雌马酚及其衍生物作为新型辐射防护剂和细胞保护剂的医药用途 |
| EP4684834A1 (de) | 2024-07-26 | 2026-01-28 | BRIU GmbH | Kristallformen onkologisch wirksamer imipridone und verfahren zu deren herstellung |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2150062A1 (de) * | 1971-10-07 | 1973-04-12 | Boehringer Sohn Ingelheim | Imidazo- eckige klammer auf 1,2-a eckige klammer zu -pyrido- eckige klammer auf 4,3-d eckige klammer zu -pyrimidine, deren saeureadditionssalze und verfahren zu deren herstellung |
| US4783450A (en) | 1987-04-13 | 1988-11-08 | Warner-Lambert Company | Use of commercial lecithin as skin penetration enhancer |
| US7635690B2 (en) * | 1999-01-22 | 2009-12-22 | Emory University | HIV-1 mutations selected for by β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine |
| NZ535349A (en) * | 2002-03-08 | 2007-01-26 | Signal Pharm Inc | JNK inhibitors with chemotherapeutic agents in a combination therapy for treating or preventing cancer and other proliferative disorders in refractory patients in particular |
| CN103169729A (zh) * | 2005-02-18 | 2013-06-26 | 阿布拉科斯生物科学有限公司 | 治疗剂的组合和给予方式以及联合治疗 |
| US20080221135A1 (en) * | 2005-05-13 | 2008-09-11 | Bristol-Myers Squibb Company | Combination therapy |
| AU2009324464B2 (en) * | 2008-12-11 | 2016-05-05 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| US9724337B2 (en) * | 2009-04-21 | 2017-08-08 | University Of Kentucky Research Foundation | AG-205 for the treatment of breast cancer |
| CA2795952A1 (en) | 2010-04-16 | 2011-10-20 | Curis, Inc. | Treatment of cancers having k-ras mutations |
| JP5863058B2 (ja) * | 2010-05-17 | 2016-02-16 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | １Ｈ−イミダゾ［４，５−ｃ］キノリン |
| US8735386B2 (en) * | 2010-07-23 | 2014-05-27 | Boehringer Ingelheim International Gmbh | Aminopyrazoloquinazolines |
| WO2012138789A2 (en) * | 2011-04-04 | 2012-10-11 | Netherlands Cancer Institute | Methods and compositions for predicting resistance to anticancer treatment |
| RS67757B1 (sr) * | 2011-04-29 | 2026-03-31 | Penn State Res Found | Indukcija malim molekulom trail gena u normalnim i tumorskim ćelijama kao antikancerska terapija |
| US8377946B1 (en) * | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
| PL2968294T3 (pl) | 2013-03-13 | 2019-10-31 | Oncoceutics Inc | 7-Benzylo-10-(2-metylobenzylo)-2,6,7,8,9,10-heksahydroimidazo[1,2-a]pirydo[4,3-d]pirymidyn-5(3H)-on do zastosowania w leczeniu nowotworu |
| SMT201900291T1 (it) | 2013-11-15 | 2019-07-11 | Oncoceutics Inc | 7-benzil-4-(2-metilbenzil)-2,4,6,7,8,9-esaidriomidazo[1,2-a]pirido[3,4-e]pirimidin-5(1h)-one, suoi sali e metodi d'uso |
| HUE069651T2 (hu) * | 2014-03-31 | 2025-03-28 | Scripps Research Inst | Farmakofór TRAIL indukcióra |
-
2014
- 2014-09-12 SM SM20190291T patent/SMT201900291T1/it unknown
- 2014-09-12 KR KR1020237045471A patent/KR102742700B1/ko active Active
- 2014-09-12 CN CN201480070502.XA patent/CN106163524B/zh active Active
- 2014-09-12 IL IL296386A patent/IL296386B2/en unknown
- 2014-09-12 HU HUE14861931A patent/HUE043291T2/hu unknown
- 2014-09-12 LT LTEP19158371.5T patent/LT3546461T/lt unknown
- 2014-09-12 PL PL14861931T patent/PL3068401T3/pl unknown
- 2014-09-12 JP JP2016554306A patent/JP6670751B2/ja active Active
- 2014-09-12 EP EP19158371.5A patent/EP3546461B1/en active Active
- 2014-09-12 PT PT191583715T patent/PT3546461T/pt unknown
- 2014-09-12 ME MEP-2019-129A patent/ME03387B/me unknown
- 2014-09-12 ES ES19158371T patent/ES2895600T3/es active Active
- 2014-09-12 SI SI201431890T patent/SI3546461T1/sl unknown
- 2014-09-12 WO PCT/US2014/055373 patent/WO2015073109A1/en not_active Ceased
- 2014-09-12 RS RS20211310A patent/RS62572B1/sr unknown
- 2014-09-12 SG SG10201809189UA patent/SG10201809189UA/en unknown
- 2014-09-12 EP EP14861931.5A patent/EP3068401B1/en active Active
- 2014-09-12 HR HRP20190814TT patent/HRP20190814T1/hr unknown
- 2014-09-12 EP EP26190229.0A patent/EP4792889A2/en active Pending
- 2014-09-12 EP EP21183202.7A patent/EP3939594B1/en active Active
- 2014-09-12 LT LTEP14861931.5T patent/LT3068401T/lt unknown
- 2014-09-12 HU HUE19158371A patent/HUE056389T2/hu unknown
- 2014-09-12 CA CA2930535A patent/CA2930535C/en active Active
- 2014-09-12 ES ES14861931T patent/ES2724331T3/es active Active
- 2014-09-12 RS RS20190518A patent/RS58745B1/sr unknown
- 2014-09-12 DK DK19158371.5T patent/DK3546461T3/da active
- 2014-09-12 KR KR1020167015829A patent/KR102318238B1/ko active Active
- 2014-09-12 MX MX2016006318A patent/MX2016006318A/es active IP Right Grant
- 2014-09-12 KR KR1020227034791A patent/KR20220140042A/ko not_active Ceased
- 2014-09-12 DK DK14861931.5T patent/DK3068401T3/da active
- 2014-09-12 TR TR2019/06711T patent/TR201906711T4/tr unknown
- 2014-09-12 PL PL19158371T patent/PL3546461T3/pl unknown
- 2014-09-12 MX MX2020002814A patent/MX390132B/es unknown
- 2014-09-12 SI SI201431203T patent/SI3068401T1/sl unknown
- 2014-09-12 SM SM20210607T patent/SMT202100607T1/it unknown
- 2014-09-12 BR BR112016011072-2A patent/BR112016011072B1/pt active IP Right Grant
- 2014-09-12 IL IL311202A patent/IL311202A/en unknown
- 2014-09-12 CA CA3204925A patent/CA3204925A1/en active Pending
- 2014-09-12 PT PT14861931T patent/PT3068401T/pt unknown
- 2014-09-12 KR KR1020217034110A patent/KR102453679B1/ko active Active
- 2014-09-12 KR KR1020247040934A patent/KR20250006309A/ko active Pending
- 2014-09-12 HR HRP20211653TT patent/HRP20211653T8/hr unknown
- 2014-09-12 EA EA201691008A patent/EA033744B1/ru unknown
- 2014-09-12 CN CN201910972122.XA patent/CN110669047A/zh active Pending
- 2014-09-12 AU AU2014349150A patent/AU2014349150B2/en active Active
-
2016
- 2016-05-11 IL IL245603A patent/IL245603B/en active IP Right Grant
- 2016-05-13 MX MX2022001966A patent/MX2022001966A/es unknown
-
2019
- 2019-05-14 CY CY20191100520T patent/CY1121628T1/el unknown
- 2019-07-24 IL IL268248A patent/IL268248B/en active IP Right Grant
- 2019-12-24 JP JP2019233099A patent/JP2020097577A/ja active Pending
-
2020
- 2020-02-06 AU AU2020200875A patent/AU2020200875B2/en active Active
-
2021
- 2021-03-24 IL IL281785A patent/IL281785B/en unknown
- 2021-11-02 CY CY20211100939T patent/CY1124832T1/el unknown
- 2021-12-05 IL IL288674A patent/IL288674B2/en unknown
-
2022
- 2022-05-06 JP JP2022076459A patent/JP2022105170A/ja active Pending
- 2022-05-06 AU AU2022203043A patent/AU2022203043B2/en active Active
-
2024
- 2024-02-27 JP JP2024027134A patent/JP7870305B2/ja active Active
- 2024-12-12 AU AU2024278350A patent/AU2024278350A1/en active Pending
-
2026
- 2026-02-11 JP JP2026020546A patent/JP2026086693A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4328229A3 (en) | Substituted heterocyclic fused cyclic compound, preparation method therefor and pharmaceutical use thereof | |
| JP2015508103A5 (enExample) | ||
| PH12017500276A1 (en) | Aminopyrimidinyl compounds as jak inhibitors | |
| JP2014221779A5 (enExample) | ||
| EP4227304A3 (en) | Thiadiazole analogs and their use for treating diseases associated with a deficiency of smn motor neurons | |
| JP2017514910A5 (enExample) | ||
| JP2016532715A5 (enExample) | ||
| JP2017508782A5 (enExample) | ||
| JP2015078230A5 (enExample) | ||
| CY1120248T1 (el) | Ενωσεις ιμιδαζο[4,5-c]κινολιν-2-ονης και η χρηση τους στη θεραπευτικη αντιμετωπιση του καρκινου | |
| EP4241772A3 (en) | Process for the preparation of compounds useful for treating spinal muscular atrophy | |
| JP2016528301A5 (enExample) | ||
| JP2017501237A5 (enExample) | ||
| JP2016514159A5 (enExample) | ||
| JP2011105738A5 (enExample) | ||
| JP2016518328A5 (enExample) | ||
| JP2016507581A5 (enExample) | ||
| JP2018521020A5 (enExample) | ||
| JP2015508092A5 (enExample) | ||
| JP2018501215A5 (enExample) | ||
| RU2021102805A (ru) | 4,6-ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-a]ПИРАЗИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ | |
| JP2017517565A5 (enExample) | ||
| CY1119231T1 (el) | Θειαδιαζολιδινοδιονες ως αναστολεις της gsk-3 | |
| CY1122077T1 (el) | Νεα δακτυλιωμενα φαινοξυακεταμιδια | |
| CR20160456A (es) | Compuestos de heteroarilo o arilo bibíclicos fusionados |